Although differences in soluble EPCR levels in patients with peripheral ischemic disease and control subjects may have multifactorial causes, both related and unrelated to ischemia, future studies should examine in more detail the impact of preventive or therapeutic strategies targeting endothelial EPCR expression to modulate the angiogenic capacities of the endothelium. The gene discussed is PROCR; the disease is ischemia.